Showing 7101-7110 of 9134 results for "".
- Encore Dermatology Inc. Launches TridesilonTM (desonide) Cream, 0.05% for ADhttps://practicaldermatology.com/news/encore-dermatology-inc-launches-tridesilontm-desonide-cream-005-for-ad/2458318/Encore Dermatology Inc. is rolling out TridesilonTM (desonide) Cream, 0.05% in a 60g tube for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Encore Dermatology Inc. licensed Tride
- L'Oréal Buys CeraVe, AcneFree and AMBI from Valeanthttps://practicaldermatology.com/news/loral-buys-cerave-acnefree-and-ambi-from-valeant/2458322/Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in the first quarter of
- Scarless Wound Healing Breakthrough: Researchers Turn Myofibroblasts in Wounds into Adipocyteshttps://practicaldermatology.com/news/scarless-wound-healing-breakthrough-researchers-turn-myofibroblasts-in-wounds-into-adipocytes/2458326/Scientists can now transform myofibroblasts found in wounds into adipocytes, paving the way toward scarless healing. Researchers began this work at the Perelman School of Medicine at the University of Pennsylvania, which led to a large-scale, multi-year study in connection with the P
- La Roche-Posay and George Washington University Publish International Study on Sun Protection Behavior and Skin Cancer Awarenesshttps://practicaldermatology.com/news/la-roche-posay-and-george-washington-university-publish-international-study-on-sun-protection-behavior-and-skin-cancer-awareness/2458327/A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographical inequalities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need
- Study Examines Diversity in Dermatologic Clinical Trialshttps://practicaldermatology.com/news/study-examines-diversity-in-dermatologic-clinical-trials/2458332/Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States, according to a new report publishe
- Revance Starts Phase III Program for Injectable Toxin in Frown Lineshttps://practicaldermatology.com/news/revance-starts-phase-iii-program-for-injectable-toxin-in-frown-lines/2458330/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials follo
- EZDERM Partners With Healthmonix to Provide Integrated MIPS Reporting for Dermatologistshttps://practicaldermatology.com/news/ezderm-partners-with-healthmonix-to-provide-integrated-mips-reporting-for-dermatologists/2458337/EZDERM, LLC and Healthmonix have partnered to integrate the MIPSPRO platform into the EZDERM suite of dermatology software solutions, including the integrated EZDERM Electronic Health Record and Practice Management systems. This partnership gives EZDERM clients access to education,
- Dermavant Licenses Portola Pharma's Cerdulatinib For Skin Applicationshttps://practicaldermatology.com/news/dermavant-licenses-portola-pharmas-cerdulatinib-for-skin-applications/2458338/Dermavant Sciences has licensed cerdulatinib from Portola Pharma for topical dermatologic applications. Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients
- Melanoma Incidence, Mortality On The Risehttps://practicaldermatology.com/news/melanoma-incidence-mortality-on-the-rise/2458339/Melanoma incidence and mortality is on the rise, according to a research letter published online by JAMA Dermatology. An estimated 76,380 Americans will be diagnosed with melanoma in 2016, and
- Oculus Innovative Sciences' SebuDerm Gel Availablehttps://practicaldermatology.com/news/fda-clears-oculus-innovative-sciences-sebuderm-gel/2458340/Oculus Innovative Sciences, Inc.’s Microcyn-based SebuDerm Gel is available in the US. As a prescription product, SebuDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrhea and seborrheic dermatitis. The gel, which